Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics Portfolio News / By Karina Tin June 16, 2022 Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics Read More »
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis Portfolio News / By Karina Tin June 13, 2022 Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis Read More »
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity Portfolio News / By Karina Tin June 5, 2022 eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity Read More »
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development Portfolio News / By Karina Tin May 26, 2022 Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development Read More »
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy Portfolio News / By Karina Tin May 26, 2022 Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy Read More »
RAPT Therapeutics Announces Private Placement Financing of $50 Million Portfolio News / By Karina Tin May 25, 2022 RAPT Therapeutics Announces Private Placement Financing of $50 Million Read More »
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022 Portfolio News / By Karina Tin May 24, 2022 NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022 Read More »
RAPT Therapeutics Announces Initiation of Phase 2B Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis Portfolio News / By Karina Tin May 23, 2022 RAPT Therapeutics Announces Initiation of Phase 2B Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis Read More »
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis Portfolio News / By Karina Tin May 18, 2022 Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis Read More »
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas Portfolio News / By Karina Tin May 17, 2022 Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas Read More »
